¼±Åà - È­»ìǥŰ/¿£ÅÍŰ ´Ý±â - ESC

 
"Trans Action"¿¡ ´ëÇÑ °Ë»ö °á°úÀÔ´Ï´Ù. °Ë»ö °á°ú º¸´Â µµÁß¿¡ Tab ۸¦ ´©¸£½Ã¸é °Ë»ö âÀÌ ¼±Åõ˴ϴÙ.
À̰ÍÀ» ¿øÇϼ̽À´Ï±î?
´ëÇÑÀÇÇù ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 3
  • ¿µ¹®
    ÇѱÛ
  • interferential action
    °£¼·ÀÛ¿ë
  • monophasic action potential
    ´Ü»óȰµ¿ÀüÀ§
  • mass action
    Áú·®ÀÛ¿ë
  • nerve action potential
    ½Å°æÈ°µ¿ÀüÀ§
  • neurotropic action
    Çâ½Å°æÀÛ¿ë
  • photochemical action
    ±¤È­ÇÐÀÛ¿ë
  • polyphasic action potential
    ´Ù»óȰµ¿ÀüÀ§
  • primary action
    ÀÏÂ÷ÀÛ¿ë
  • promotor action
    ÃËÁøÀÛ¿ë
  • pharmacological action
    ¾à¸®ÀÛ¿ë
  • reflex action
    ¹Ý»çÀÛ¿ë
  • reverse action clasp
    ¿ªÀÛ¿ë°¥°í¸®
  • specific action
    ƯÀÌÀÛ¿ë
  • synergistic action
    »ó½ÂÀÛ¿ë
  • sensory nerve action potential
    °¨°¢½Å°æÈ°µ¿ÀüÀ§
¿¾ ´ëÇÑÀÇÇù ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 3
  • ¿µ¹®
    ÇѱÛ
  • neurotropic action
    Çâ½Å°æÀÛ¿ë
  • pharmacological action
    ¾à¸®ÀÛ¿ë
  • photochemical action
    ±¤È­ÇÐÀÛ¿ë
  • primary action
    ÀÏÂ÷ÀÛ¿ë, ÀÏÂ÷±â´É
  • promotor action
    ÃËÁøÀÛ¿ë
  • reflex action
    ¹Ý»çÀÛ¿ë
  • specific action
    ƯÀÌÀÛ¿ë
  • synergistic action
    »ó½ÂÀÛ¿ë
  • thermogenic action
    ¹ß¿­ÀÛ¿ë
  • trigger action
    ¹æ¾Æ¼èÀÛ¿ë, À¯¹ßÀÛ¿ë
  • biphasic action potential
    ÀÌ»óȰµ¿ÀüÀ§
  • compound muscle action potential
    (¢¡muscle) º¹ÇÕ±ÙȰµ¿ÀüÀ§
  • compound nerve action potential
    (¢¡nerve) º¹ÇսŰæÈ°µ¿ÀüÀ§
  • reverse action clasp
    ¿ªÀÛ¿ë°¥°í¸®
  • monophasic action potential
    ´Ü»óȰµ¿ÀüÀ§
¿¾ ´ëÇÑÀÇÇù 2 ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 3
  • ¿µ¹®
    ÇѱÛ
  • indirect action
    °£Á¢ÀÛ¿ë
  • inhibitory action
    ÀúÁöÀÛ¿ë(îÁò­íÂéÄ).
  • inotropic action
    º¯·ÂÀÛ¿ë(ܨÕôíÂéÄ), ¼öÃàÃËÁøÀÛ¿ë(â¥õêõµòäíÂéÄ).³»°ú¼öÃà·Â
  • inotropic action
    º¯·ÂÀÛ¿ë, ¼öÃàÃËÁøÀÛ¿ë.[³»°ú]¼öÃà·Â º¯µ¿ÀÛ¿ë.
  • pharmacodynamic action
    ¾à¿ªÇÐ(Àû) ÀÛ¿ë(å·æ³ùÊ(îÜ) íÂéÄ).
  • photochemical action
    ±¤È­ÇÐÀÛ¿ë(ÊÙËöËí).
  • photodynamic action
    ±¤¿ªÇÐÀÛ¿ë(ÎÃæ³ùÊ íÂéÄ).
  • physical action
    ¹°¸®Àû ÀÛ¿ë(¡­íÂéÄ).
  • physiological action
    »ý¸®ÀÛ¿ë(¡­íÂéÄ).
  • primary action
    ÀÏÂ÷±â´É
  • principle of least action
    ÃÖ¼ÒÀÛ¿ëÀÇ ¿ø¸®(õÌá´íÂéÄ¡­ê«ìµ).
  • prolonged action drug
    Áö¼Ó¼º ¾àÁ¦(ò¥áÙàõå·ð¥).
  • prolonged action drug
    Ưȿ¼º ¾àÁ¦(÷åüùàõå·ð¥), Áö¼Ó¼º ¾àÁ¦(ò¥áÙàõå·ð¥).
  • promotor action
    ÃËÁøÀÛ¿ë.
  • protoplasmic action
    ¿øÇüÁúÀÛ¿ë(¡­íÂéÄ).
¿¾ ´ëÇÑÀÇÇù 3 ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 3
  • ¿µ¹®
    ÇѱÛ
  • central action
    ÁßÃßÀÛ¿ë(ñéõÒíÂéÄ).
  • chronotropic action
    ½É¹Ú¼öº¯µ¿ÀÛ¿ë, º¯½ÃÀÛ¿ë(¡­íÂéÄ)
  • chronotropic action
    º¯½ÃÀÛ¿ë
  • ciliary action
    ¼¶¸ðÀÛ¿ë.
  • clinotropic action
    º¯°æ»çÀÛ¿ë(ܨÌËÞØíÂéÄ).
  • cochlear action potential
    ¿Í¿ì Ȱµ¿ÀüÀ§
  • colloidoclastic action
    ÄÝ·ÎÀ̵åÆÄ±«ÀÛ¿ë(¡­÷òÎÕíÂéÄ).
  • competitive action
    °æÀïÀÛ¿ë(Ìæî³íÂéÄ).
  • competitive action
    »ó°æÀÛ¿ë.
  • compound action potential
    º¹ÇÕ È°µ¿Àü¾Ð(ÜÜùêüÁÔÑï³äâ)
  • compound action potential
    º¹ÇÕȰµ¿Àü¾Ð(ÜÜùêüÀÔÑï³äâ).
  • concentrating action
    ³óÃàÀÛ¿ë
  • corrective action
    ±³Á¤Ã³Ä¡(¡­ô¥öÇ).
  • corrosive action
    ºÎ½ÄÀÛ¿ë(¡­íÂéÄ).
  • cumulative action
    ´©ÀûÀÛ¿ë.¸¶ÃëÃàÀûÀÛ¿ë.
KMLE ÀÇÇоà¾î »çÀü À¯»ç °Ë»ö °á°ú : 5 ÆäÀÌÁö: 3
TFM Trans-Formational Migrane
TTA Trans-Tracheal Aspiration
TUR Trans-Urethral Resection; °æ¿äµµ ÀýÁ¦¼ú
TURP Trans-Urethral Resection of the Prostate; ¿äµµ½Ä (Àü¸³¼±) ÀýÁ¦¼ú
TVH Trans-Vaginal Hysterectomy
KMLE ÀÚµ¿ÃßÃâ ÀÇÇоà¾î »çÀü À¯»ç °Ë»ö °á°ú : 5 ÆäÀÌÁö: 3
APD90 action potential durations at 90% repolarization
CAP cochlea action potentials
CAP Compound Action Potential
CMAP Compound motor action potential
CMAP Compound muscle action potential
°æºÏ´ë Ä¡°ú´ëÇÐ ±¸°­³»°ú ±³½Ç »çÀü À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 3
  • ¿µ¹®
    ÇѱÛ
    ¼³¸í
  • electrolytic action
    ÀüÇØ ÀÛ¿ë
  • fungicidal action
    »ìÁø±Õ ÀÛ¿ë
  • hemostatic action
    ÁöÇ÷ ÀÛ¿ë
    ÃâÇ÷À» ¸ØÃß°Ô ÇÏ´Â ÀÛ¿ë. ÈçÈ÷ 'ÁöÇ÷'À̶ó ºÎ¸¥´Ù.
  • hormone like action
    È£¸£¸ó À¯»ç ÀÛ¿ë
    ü³»¿¡ µé¾î¿Í È£¸£¸ó°ú ºñ½ÁÇÑ ¿ªÇÒÀ» ÇÏ´Â °Í.
  • immediate action
    Áï°¢ ÀÛ¿ë
  • least action
    ÃÖ¼Ò ÀÛ¿ë
  • nicotinic action
    ´ÏÄÚÆ¾ ÀÛ¿ë
  • onset of action
    ÀÛ¿ë½ÃÀÛ
  • permissive action
    Çã¿ë ÀÛ¿ë
  • pharmacological action
    ¾à¸® ÀÛ¿ë
  • physiological action
    »ý¸® ÀÛ¿ë
  • presynaptic inhibitory action
    ½Ã³³½ºÀü ¾ïÁ¦ ÀÛ¿ë
  • reflex action
    ¹Ý»ç Ȱµ¿
  • reverse action
    ¹Ý´ë ÀÛ¿ë
  • reversible action
    °¡¿ª ÀÛ¿ë
CancerWEB ¿µ¿µ ÀÇÇлçÀü À¯»ç °Ë»ö °á°ú : 11 ÆäÀÌÁö: 3
trans-activation (genetics) Increased rate of gene expression directed by either viral or cellular proteins. These regulatory factors (diffusible gene products) act in trans -- that is, act on homologous or heterologous molecules of DNA. (cis-acting factors act only on homologous molecules.)
(12 Dec 1998)
trans-activators Diffusible gene products that act on homologous or heterologous molecules of viral or cellular DNA to regulate the expression of proteins.
(12 Dec 1998)
trans-bronchial biopsy <chest medicine, procedure> A biopsy that is performed through the wall of the bronchus (using the bronchoscope). This involves obtaining a small piece of lung tissue for microscopic analysis. This is a useful alternative to an open surgical biopsy, where an incision must be made.
(17 Mar 1998)
trans configuration 1. <chemistry> The configuration of an organic molecule containing a double bond between two carbon atoms, where the largest, most complex R groups attached to each carbon are on opposite sides.
Alternatively: The configuration of an organic molecule containing a ring, where the largest, most complex R groups attached to each carbon are on opposite sides.
These configurations are the opposite of cis configuration.
2. <genetics> A genetics term meaning that the changes in gene expression are due to something acting on the gene from a distance, or from an unrelated location, rather than on the same strand of DNA.
Two mutations in different genes coding for the same phenotype which are on opposite homologous chromosomes (as opposed to the cis configuration where both of the mutations are on the same homologue).
(17 Mar 1998)
trans Golgi network <cell biology> A complex of membranous tubules and vesicles, near the trans face of the Golgi, which is thought to be a major intersection for intracellular traffic of vesicles.
(18 Nov 1997)
trans-Golgi reticulum That part of the Golgi apparatus that takes newly processed proteins and delivers them to secretory vesicles that will fuse with other biomembranes (e.g., the plasma membrane).
(05 Mar 2000)
trans-octaprenyltranstransferase <enzyme> Level of isopentenyl diphosphate-magnesium(ipp-mg) is decisive in affecting the chain length of the products of prenyltransferase reaction
Registry number: EC 2.5.1.11
Synonym: solanesyl diphosphate synthase, solanesyl pyrophosphate synthetase
(26 Jun 1999)
trans-pentaprenyltranstransferase <enzyme> From micrococcus luteus b-p26; composed of 2 components; requires all-trans farnesyl or all-trans-geranylgeranyl pyrophosphate
Registry number: EC 2.5.1.33
Synonym: all-trans-hexaprenylpyrophosphate synthase, hexaprenyldiphosphate synthetase, trans-pentaprenyltransferase, hexaprenylpyrophosphate synthetase
(26 Jun 1999)
trans-retinal The orange retinaldehyde resulting from the action of light on the rhodopsin of the retina, which converts the 11-cis-retinal component of the rhodopsin to all-trans-retinal plus opsin.
Synonym: trans-retinal, visual yellow.
(05 Mar 2000)
trans splicing <molecular biology> Relating to RNA splicing of two different pre mRNA molecules together. Seems to rely on intron like sequences.
Contrasts with the normal cis splicing of conventional RNA molecules.
(19 Jan 1998)
trans-splicing Formation of spliced products containing portions of two different transcripts.
(05 Mar 2000)
ÀÌ ¾Æ·¡ ºÎÅÍ´Â °á°ú°¡ ¾ø½À´Ï´Ù.
KMLE ¾àǰ/ÀǾàǰ ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 3
  • Á¦Ç°¸í
    ¼ººÐ/ÇÔ·®
    ±¸ºÐ/º¸Çè±Þ¿©
KMLE ¾àǰ/ÀǾàǰ À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 3
  • Á¦Ç°¸í
    ¼ººÐ/ÇÔ·®
    ±¸ºÐ/º¸Çè±Þ¿©
¾Ë±â½¬¿î ÀÇÇпë¾îÇ®ÀÌÁý, ¼­¿ïÀÇ´ë ±³¼ö ÁöÁ¦±Ù, °í·ÁÀÇÇÐ ÃâÆÇ ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 3
¾Ë±â½¬¿î ÀÇÇпë¾îÇ®ÀÌÁý, ¼­¿ïÀÇ´ë ±³¼ö ÁöÁ¦±Ù, °í·ÁÀÇÇÐ ÃâÆÇ À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 3
´ëÇÑÀÇÇù ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 3
  • ¿µ¹®
    ÇѱÛ
´ëÇÑÀÇÇù Çʼö ÀÇÇпë¾îÁý »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 3
  • ¿µ¹®
    ÇѱÛ
´ëÇÑÀÇÇù Çʼö ÀÇÇпë¾îÁý »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 3
  • ¿µ¹®
    ÇѱÛ
¿¾ ´ëÇÑÀÇÇù ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 3
  • ¿µ¹®
    ÇѱÛ
¿¾ ´ëÇÑÀÇÇù 2 ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 3
  • ¿µ¹®
    ÇѱÛ
¿¾ ´ëÇÑÀÇÇù 3 ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 3
  • ¿µ¹®
    ÇѱÛ
´ëÇÑÇØºÎÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 3
  • ¿µ¹®
    ÇѱÛ
´ëÇÑÇØºÎÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 3
  • ¿µ¹®
    ÇѱÛ
´ëÇѽŰæ¿Ü°úÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 3
  • ¿µ¹®
    ÇѱÛ
    ÇÑÀÚ
´ëÇѽŰæ¿Ü°úÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 3
  • ¿µ¹®
    ÇѱÛ
    ÇÑÀÚ
´ëÇѱâ»ýÃæÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 3
  • ¿µ¹®
    ÇѱÛ
´ëÇѱâ»ýÃæÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 3
  • ¿µ¹®
    ÇѱÛ
´ëÇÑ»ýÈ­ÇкÐÀÚ»ý¹°ÇÐȸ ¿ë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 3
  • ¿µ¹®
    ÇѱÛ
´ëÇÑ»ýÈ­ÇкÐÀÚ»ý¹°ÇÐȸ ¿ë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 3
  • ¿µ¹®
    ÇѱÛ
KI ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 3
  • ¿µ¹®
    ÇѱÛ
KI ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 3
  • ¿µ¹®
    ÇѱÛ
KMLE ÀÇÇоà¾î »çÀü ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 3
KMLE ÀÚµ¿ÃßÃâ ÀÇÇоà¾î »çÀü ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 3
ÀÇÇÐ³í¹® ¾àÀÚ(Pubmed/Entrez) °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 3
Çѱ¹Ç¥ÁØÁúº´»çÀκзù ¾àÀÚ ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 3
  • ÄÚµå
    ¿µ¹®
    ÇѱÛ
Çѱ¹Ç¥ÁØÁúº´»çÀκзù ¾àÀÚ À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 3
  • ÄÚµå
    ¿µ¹®
    ÇѱÛ
°æºÏ´ë Ä¡°ú´ëÇÐ ±¸°­³»°ú ±³½Ç »çÀü ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 3
  • ¿µ¹®
    ÇѱÛ
    ¼³¸í
CancerWEB ¿µ¿µ ÀÇÇлçÀü ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 3
MeSH(Medical Subject Headings) ¸ÂÃã °Ë»ö (http://www.nlm.nih.gov) °á°ú : 0 ÆäÀÌÁö: 3
MeSH(Medical Subject Headings) À¯»ç °Ë»ö (http://www.nlm.nih.gov) °á°ú : 0 ÆäÀÌÁö: 3
¿ÜºÎ ¸µÅ© - Merriam-Webster's ÀÇÇлçÀü ¸ÂÃã °Ë»ö (https://www.merriam-webster.com) °á°ú: 0 ÆäÀÌÁö: 3
¿ÜºÎ ¸µÅ© - Merriam-Webster's ÀÇÇлçÀü À¯»ç °Ë»ö (https://www.merriam-webster.com) °á°ú: 0 ÆäÀÌÁö: 3
¿ÜºÎ ¸µÅ© - A.D.A.M. Medical Encyclopedia ¸ÂÃã °Ë»ö (http://www.nlm.nih.gov) °á°ú: 0 ÆäÀÌÁö: 3
¿ÜºÎ ¸µÅ© - A.D.A.M. Medical Encyclopedia À¯»ç °Ë»ö (http://www.nlm.nih.gov) °á°ú: 0 ÆäÀÌÁö: 3
¿ÜºÎ ¸µÅ© - MedlinePlus Health Topics ¸ÂÃã °Ë»ö (http://www.nlm.nih.gov) °á°ú: 0 ÆäÀÌÁö: 3
¿ÜºÎ ¸µÅ© - MedlinePlus Health Topics À¯»ç °Ë»ö (http://www.nlm.nih.gov) °á°ú: 0 ÆäÀÌÁö: 3
¿ÜºÎ ¸µÅ© - µå·¯±×ÀÎÆ÷ ¾àÇÐ Á¤º¸ ¸ÂÃã °Ë»ö (http://www.druginfo.co.kr) °á°ú: 0 ÆäÀÌÁö: 3
Á¦Ç°¸í
ÆÇ¸Å»ç
º¸ÇèÄÚµå ¼ººÐ/ÇÔ·®
±¸ºÐ/º¸Çè±Þ¿©
¿ÜºÎ ¸µÅ© - µå·¯±×ÀÎÆ÷ ¾àÇÐ Á¤º¸ À¯»ç °Ë»ö (http://www.druginfo.co.kr) °á°ú: 0 ÆäÀÌÁö: 3
Á¦Ç°¸í
ÆÇ¸Å»ç
º¸ÇèÄÚµå ¼ººÐ/ÇÔ·®
±¸ºÐ/º¸Çè±Þ¿©
¿ÜºÎ ¸µÅ© - WebMD.com Drug Reference ¸ÂÃã °Ë»ö (http://www.webmd.com) °á°ú: 0 ÆäÀÌÁö: 3
¿ÜºÎ ¸µÅ© - WebMD.com Drug Reference À¯»ç °Ë»ö (http://www.webmd.com) °á°ú: 0 ÆäÀÌÁö: 3
¿ÜºÎ ¸µÅ© - Drug.com Drugs by Medical Condition ¸ÂÃã °Ë»ö (http://www.drugs.com) °á°ú: 0 ÆäÀÌÁö: 3
¿ÜºÎ ¸µÅ© - Drug.com Drugs by Medical Condition À¯»ç °Ë»ö (http://www.drugs.com) °á°ú: 0 ÆäÀÌÁö: 3
KMLE À¥ ¿ë¾î ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 3
KMLE À¥ ¿ë¾î À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 3
ÇÑ¿µ/¿µÇÑ »çÀü ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 3
  • ¿µ¹®
    ÇѱÛ
ÇÑ¿µ/¿µÇÑ »çÀü À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 3
  • ¿µ¹®
    ÇѱÛ
WordNet ÀÏ¹Ý ¿µ¿µ »çÀü °Ë»ö °á°ú : 0 ÆäÀÌÁö: 3
¿ÜºÎ ¸µÅ© - American Heritage Dictionary ¿µ¿µ»çÀü ¸ÂÃã °Ë»ö (https://www.ahdictionary.com) °á°ú: 0 ÆäÀÌÁö: 3
¿ÜºÎ ¸µÅ© - American Heritage Dictionary ¿µ¿µ»çÀü À¯»ç °Ë»ö (https://www.ahdictionary.com) °á°ú: 0 ÆäÀÌÁö: 3
ÅëÇÕ°Ë»ö ¿Ï·á